查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589465

糖尿病视网膜病变市场：按类型、管理划分 - 2025-2030 年全球预测

Diabetic Retinopathy Market by Type (Non-proliferative DR, Proliferative DR), Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病视网膜病变市值为3.7638亿美元，预计到2024年将达到4.4148亿美元，复合年增长率为17.69%，到2030年将达到11.772亿美元。

糖尿病视网膜病变（DR）是一种由糖尿病引起的眼科疾病，会影响视网膜血管并导致视力障碍和失明。此市场分析的范围包括目前的诊断技术、药物治疗、雷射治疗以及旨在管理或治疗 DR 的预防性治疗方法。全球糖尿病人口不断增长以及糖尿病相关併发症发生率不断增加，因此需要有效的 DR 管理。早期发现和早期管理对于预防严重视力丧失至关重要，使其成为一个具有丰富应用选择的领域，包括眼科诊所、医院、门诊手术中心和眼科专科病房。主要市场驱动因素包括医学影像处理技术的进步、意识提升倡议以及政府对糖尿病和眼部健康措施的资助。值得注意的是，人工智慧主导的诊断工具和远端医疗解决方案的开发提供了最新的潜在机会。公司可以从智慧型手机眼底摄影机和穿戴式监测设备等创新技术的投资中受益。然而，由于先进诊断设备的成本高昂、缺乏熟练的医疗保健专业人员以及进入医疗服务机会有限的农村地区的挑战，市场成长面临限制。此外，监管挑战和治疗方案的潜在副作用正在阻碍市场扩张。儘管存在这些挑战，但针对每位患者 DR 的独特进展，微创治疗方案和个人化医疗方法仍有创新的机会。竞争激烈的市场需要药物配方和诊断技术的持续创新，重点是成本效率和可近性。与科技公司和研究机构的伙伴关係可以产生重要的见解，加速突破，并使公司处于视力保健市场的前沿。总体而言，平衡技术进步与可负担性和可近性对于占领新兴市场和解决未满足的需求至关重要。

主要市场统计
基准年[2023] 37638万美元
预测年份 [2024] 44148万美元
预测年份 [2030] 11.772 亿美元
复合年增长率（%） 17.69%

市场动态：快速发展的糖尿病视网膜病变市场的关键市场洞察

供需的动态交互作用正在改变糖尿病视网膜病变市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球糖尿病盛行率上升
    • 提高对糖尿病管理和护理的认识
    • 政府推动糖尿病管理的倡议
  • 市场限制因素
    • 缺乏熟练的眼科医生
  • 市场机会
    • 不断引进先进的治疗方法和药物
    • 治疗糖尿病黄斑部水肿联合治疗的出现
  • 市场挑战
    • 核准糖尿病视网膜病变治疗需要时间

波特五力：驾驭糖尿病视网膜病变市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解糖尿病视网膜病变市场的外部影响

外部宏观环境因素在塑造糖尿病视网膜病变市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解糖尿病视网膜病变市场的竞争格局

对糖尿病视网膜病变市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵糖尿病视网膜病变市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病视网膜病变市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製糖尿病视网膜病变市场的成功之路

糖尿病视网膜病变市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球糖尿病盛行率正在上升
      • 提高对糖尿病管理和护理的认识
      • 政府推动糖尿病管理的倡议
    • 抑制因素
      • 缺乏熟练的眼科医生
    • 机会
      • 持续介绍先进的糖尿病视网膜病变治疗方法和药物
      • 联合疗法治疗糖尿病黄斑部水肿的出现
    • 任务
      • 糖尿病视网膜病变药物的核准过程需要时间
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 糖尿病视网膜病变市场：依类型

  • 非增殖性DR
  • 增殖性DR

第七章经营团队的糖尿病视网膜病变市场

  • 抗VEGF治疗
  • 眼内类固醇注射
  • 雷射手术
  • 玻璃体切除手术

第八章北美与南美糖尿病视网膜病变市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区糖尿病视网膜病变市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲糖尿病视网膜病变市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • BCN PEPTIDES, SAU
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Kowa Company, Ltd.
  • Novartis AG
  • Opthea Limited
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics Inc.
Product Code: MRR-742BD517D2EC

The Diabetic Retinopathy Market was valued at USD 376.38 million in 2023, expected to reach USD 441.48 million in 2024, and is projected to grow at a CAGR of 17.69%, to USD 1,177.20 million by 2030.

Diabetic Retinopathy (DR) is a diabetes-induced eye condition that affects the retinal blood vessels and can lead to vision impairment and blindness. The scope of analysis within this market includes current diagnostic technologies, pharmaceutical treatments, laser therapies, and preventive care methods aimed at managing or treating DR. The necessity for efficient DR management arises from the growing global diabetic population and the increasing incidence of diabetes-related complications. Early detection and management are critical in preventing severe vision loss, making this an area rich with application options across eye care clinics, hospitals, outpatient surgical centers, and specialized ophthalmology wards. Key market growth drivers include advancements in medical imaging technologies, heightened awareness initiatives, and government funding for diabetes and eye health initiatives. Notably, the development of AI-driven diagnostic tools and telemedicine solutions presents the latest potential opportunities. Companies can benefit by investing in innovative technologies such as smartphone fundus cameras and wearable monitoring devices. However, market growth faces limitations driven by high costs of advanced diagnostic devices, lack of skilled healthcare professionals, and challenges in reaching rural areas with limited access to healthcare services. Furthermore, the market's expansion is hindered by regulatory challenges and potential side effects of treatment options. Despite these challenges, there are opportunities in the innovation of minimally invasive treatment options and personalized medicine approaches, targeting the unique progression of DR in individual patients. The market's competitive nature demands continuous innovation in drug formulations and diagnostic techniques, emphasizing cost-efficiency and accessibility. Fostering partnerships with technology firms and research institutions can generate significant insights and foster breakthroughs, thus positioning companies at the forefront of the vision care market. Overall, balancing technological advancements with affordability and accessibility will be crucial in capturing emerging markets and addressing the substantial unmet needs in diabetic retinopathy care.

KEY MARKET STATISTICS
Base Year [2023] USD 376.38 million
Estimated Year [2024] USD 441.48 million
Forecast Year [2030] USD 1,177.20 million
CAGR (%) 17.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Retinopathy Market

The Diabetic Retinopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetes globally
    • Increasing awareness associated with diabetic management and care
    • Government initiatives to promote the diabetes management
  • Market Restraints
    • Dearth of skilled ophthalmologists
  • Market Opportunities
    • Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • Emergence of combine therapies for treatment of diabetic macular edema
  • Market Challenges
    • Time consuming approval process for diabetic retinopathy drugs

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Retinopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Retinopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Retinopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Retinopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Retinopathy Market

A detailed market share analysis in the Diabetic Retinopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Retinopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Retinopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Retinopathy Market

A strategic analysis of the Diabetic Retinopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, BCN PEPTIDES, S.A.U., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Kowa Company, Ltd., Novartis AG, Opthea Limited, Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sirnaomics Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-proliferative DR and Proliferative DR.
  • Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes globally
      • 5.1.1.2. Increasing awareness associated with diabetic management and care
      • 5.1.1.3. Government initiatives to promote the diabetes management
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
      • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Retinopathy Market, by Type

  • 6.1. Introduction
  • 6.2. Non-proliferative DR
  • 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

  • 7.1. Introduction
  • 7.2. Anti-VEGF Therapy
  • 7.3. Intraocular Steroid Injection
  • 7.4. Laser Surgery
  • 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alimera Sciences, Inc.
  • 2. Allergan PLC
  • 3. Ampio Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. BCN PEPTIDES, S.A.U.
  • 7. F. Hoffmann-La Roche AG
  • 8. Kodiak Sciences Inc.
  • 9. Kowa Company, Ltd.
  • 10. Novartis AG
  • 11. Opthea Limited
  • 12. Oxurion NV
  • 13. Pfizer Inc.
  • 14. Regeneron Pharmaceuticals Inc.
  • 15. Sirnaomics Inc.

LIST OF FIGURES

  • FIGURE 1. DIABETIC RETINOPATHY MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC RETINOPATHY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC RETINOPATHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC RETINOPATHY MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY INTRAOCULAR STEROID INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM DIABETIC RETINOPATHY MARKET SIZE, BY MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 101. DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2023